Table 2 Univariate and multivariate Cox hazard regression in TCGA cohort
From: EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
Pathological type | Characteristics | Univariate analysis Hazard Ratio (95%CI) | P value | Multivariate analysis Hazard Ratio (95%CI) | P value |
|---|---|---|---|---|---|
LUAD | EZH2 expression | 1.412 (1.013–1.967) | 0.041 | 1.386 (0.976–1.968) | 0.048 |
Age | 1.013 (1.001–1.024) | 0.026 | 1.029 (0.748–1.417) | 0.031 | |
Gender | 0.951 (0.684–1.323) | 0.767 | 1.043 (0.744–1.463) | 0.807 | |
T stage | 2.619 (1.743–3.936) | 0.000 | 1.753 (1.069–2.872) | 0.026 | |
Lymph node metastasis | 2.661 (1.906–3.713) | 0.000 | 2.330 (1.567–3.464) | 0.000 | |
Presence of distant metastasis | 1.936 (1.092–3.434) | 0.038 | 1.215 (0.630–2.343) | 0.560 | |
TNM classification | 2.775 (1.968–3.913) | 0.000 | 1.365 (0.838–2.225) | 0.212 | |
Tumor recurrence | 1.315 (1.167–1.482) | 0.000 | 1.282 (1.131–1.454) | 0.000 | |
Smoker status | 1.083 (0.826–1.419) | 0.569 | 0.930 (0.689–1.255) | 0.635 | |
LUSC | EZH2 expression | 0.966 (0.717–1.302) | 0.821 | 0.956 (0.703–1.299) | 0.773 |
Age | 1.196 (0.898–1.594) | 0.219 | 1.306 (0.966–1.765) | 0.083 | |
Gender | 0.718 (0.497–1.037) | 0.069 | 0.765 (0.528–1.109) | 0.157 | |
T stage | 1.451 (1.004–2.096) | 0.056 | 1.111 (0.716–1.724) | 0.639 | |
Lymph node metastasis | 1.098 (0.808–1.491) | 0.552 | 0.900 (0.623–1.301) | 0.576 | |
Presence of distant metastasis | 2.506 (0.925–6.791) | 0.114 | 1.839 (0.632–5.351) | 0.264 | |
TNM classification | 1.546 (1.085–2.203) | 0.020 | 1.326 (0.800–2.197) | 0.274 | |
Tumor recurrence | 1.369 (1.229–1.524) | 0.000 | 1.343 (1.202–1.500) | 0.000 | |
Smoker status | 0.619 (0.366–1.048) | 0.048 | 0.765 (0.528–1.109) | 0.127 |